Show simple item record

dc.contributor.authorDriessen, CML
dc.contributor.authorGroenewoud, JMM
dc.contributor.authorde Boer, JP
dc.contributor.authorGelderblom, H
dc.contributor.authorvan der Graaf, WTA
dc.contributor.authorPrins, JB
dc.contributor.authorKaanders, JHAM
dc.contributor.authorvan Herpen, CML
dc.date.accessioned2019-02-25T16:32:00Z
dc.date.issued2018-04
dc.identifier.citationSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018, 26 (4), pp. 1233 - 1242
dc.identifier.issn0941-4355
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3093
dc.identifier.eissn1433-7339
dc.identifier.doi10.1007/s00520-017-3946-7
dc.description.abstractPURPOSE:The CONDOR study showed that docetaxel/cisplatin/5-fluorouracil (TPF) followed by conventional radiotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 (cis100 + RT; n = 27)) versus accelerated radiotherapy with cisplatin weekly 40 mg/m2 (cis40 + ART; n = 29) in locally advanced head and neck cancer (LAHNC) patients was not feasible. Here, we report the analysis of health-related quality of life (HRQOL) of the patients entered in this study. METHODS:HRQOL was assessed at baseline, after two TPF, before start of chemoradiotherapy, and 1, 4, 8, 12, and 24 months after completion of chemoradiotherapy using the EORTC-QLQ-C30 and QLQ-H&N35 in 62 patients. RESULTS:Compliance with the QOL questionnaires was 94% (59/62) at baseline and 61% (30/49) at 12 months, respectively. HRQOL decreased after TPF and further decreased during chemoradiohteray in both arms equally. Pain and swallowing dysfunction improved significantly during TPF but deteriorated below baseline levels during chemoradiotherapy, cis40 + ART > cis100 + RT (p < 0.05). HRQOL and symptoms restored to baseline within 12 months in both arms and remained at that level until 24 months. CONCLUSIONS:After TPF, cis40 + ART had a larger negative impact on symptoms than cis100 + RT, probably due to the ART. HRQOL and symptoms restored to baseline levels within 12 months after end of treatment in both arms, which is an important perspective for patients during the phase of most serious acute side effects of treatment. TRIAL REGISTRATION:NCT00774319.
dc.formatPrint-Electronic
dc.format.extent1233 - 1242
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectHead and Neck Neoplasms
dc.subjectCisplatin
dc.subjectFluorouracil
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectFeasibility Studies
dc.subjectQuality of Life
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectChemoradiotherapy
dc.subjectInduction Chemotherapy
dc.subjectDocetaxel
dc.titleQuality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial.
dc.typeJournal Article
dcterms.dateAccepted2017-10-23
rioxxterms.versionofrecord10.1007/s00520-017-3946-7
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.licenseref.startdate2018-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.publication-statusPublished
pubs.volume26
pubs.embargo.termsNot known
icr.researchteamClinical and Translational Sarcomaen_US
dc.contributor.icrauthorvan der Graaf, Wilhelminaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0